A Phase 4 interventional study of Travoprost 0.004% ophthalmic solution and Bimatoprost 0.01% ophthalmic solution in Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-03.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.
Among the 42 studies testing travoprost in Glaucoma, this one is the 17th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2012, is one of 25 in phase 4, and was the 34th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 89 across the 39 interventional studies. Of the 41 that completed or were terminated, 18 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
93 studies in Glaucoma by Alcon: none open now, none under way, none of them phase 3. Of 92 finished, 35 (38%) have results posted.
Among the 93 studies in Glaucoma by Alcon, this one is the 44th largest by enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2012, is one of 37 in phase 4, and was the 73rd registered.
Alcon’s Glaucoma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 42 studies testing travoprost in Glaucoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 93 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is evaluate effects of TRAVATAN® versus LUMIGAN® on intraocular pressure (IOP) and ocular surface and inflammatory biomarkers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Travoprost 0.004% ophthalmic solution with Polyquad®, 1 drop to the study eye(s), once a day in the evening, for 6 months
Drug: Travoprost 0.004% ophthalmic solution
Bimatoprost 0.01% ophthalmic solution with BAK, 1 drop to the study eye(s), once a day in the evening, for 6 months
Drug: Bimatoprost 0.01% ophthalmic solution
Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
Also known as: TRAVATAN®
Ophthalmic solution containing benzalkonium chloride (BAK)
Also known as: LUMIGAN®
Mean Change From Baseline in Intraocular Pressure (IOP) at Month 6
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
Time frame: Baseline (Day 0), Month 6
Mean Change From Baseline in IOP at Week 6 and Month 3
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg. A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
Time frame: Baseline (Day 0), Week 6, Month 3
Percentage of Subjects Who Reached Target IOP at Each Visit
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg. Target IOP was defined as ≤ 18 mmHg. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
Time frame: Week 6, Month 3, Month 6
Number of Subjects With Change From Baseline in Ocular Hyperaemia by Grade at Each Visit
Ocular Hyperaemia (excess of blood in the white of the eyes (sclera)) was graded by the investigator on a 4-point scale where 0=None/Trace, 1=Mild, 2=Moderate, and 3=Severe. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
Time frame: Baseline (Day 0), Week 6, Month 3, Month 6
Number of Subjects With Change From Baseline in Corneal Staining by Grade at Month 3 and Month 6
Corneal staining was assessed after ophthalmic dye was instilled in the eye. The upper eyelid was lifted slightly, and the eye was compared to grading panels. Corneal staining was graded on a scale from 0 (absent) to 5 (severe). One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
Time frame: Baseline (Day 0), Month 3, Month 6
Number of Subjects With Change From Baseline in Conjunctiva Staining by Grade at Month 3 and Month 6
Conjunctiva staining was assessed after ophthalmic dye was instilled in the eye. The upper eyelid was lifted slightly, and the eye was compared to grading panels. Conjunctiva staining was graded on a scale from 0 (absent) to 5 (severe). One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
Time frame: Baseline (Day 0), Month 3, Month 6
Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Month 3 and Month 6
The OSDI questionnaire (used to measure vision-related function, ocular symptoms, visual function, and environmental factors that may affect vision) was answered by the subject. Each of the 12 items was scored on a 0-4 Likert scale, where 0 is "None of the time" and 4 is "All of the time." A resultant overall 0-100 score was calculated, with higher scores representing greater disability. A negative number change represents a perceived improvement in ocular health.
Time frame: Baseline (Day 0), Month 3, Month 6
Mean Change From Baseline In Tear Film Break Up Time (TBUT) at Month 3 and Month 6
TBUT (the time required for dry spots to appear on the corneal surface after blinking) was assessed by the investigator using slit lamp examination . A longer break up time is a sign of a more stable tear film. A positive number change from baseline indicates improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
Time frame: Baseline (Day 0), Month 3, Month 6
Subjects were recruited from 2 study centers located in Slovenia.
| Milestone | TRAVATAN | LUMIGAN |
|---|---|---|
| Started | 52 | 52 |
| Completed | 46 | 43 |
| Not completed | 6 | 9 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Noncompliance | 1 | 1 |
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
| mmHg | TRAVATAN | LUMIGAN |
|---|---|---|
| Baseline (Day 0) | 24.66 ± 3.65 | 24.59 ± 4.14 |
| Change from Baseline at Month 6, n=46,43 | -7.61 ± 4.32 | -7.35 ± 3.84 |
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg. A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
| mmHg | TRAVATAN | LUMIGAN |
|---|---|---|
| Change from Baseline at Week 6, n=46,46 | -7.50 ± 3.80 | -7.02 ± 3.28 |
| Change from Baseline at Month 3, n=46,44 | -7.96 ± 3.71 | -7.82 ± 3.15 |
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg. Target IOP was defined as ≤ 18 mmHg. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
| percentage of participants | TRAVATAN | LUMIGAN |
|---|---|---|
| Week 6, n=46,46 | 69.6 | 56.5 |
| Month 3, n=46,44 | 71.7 | 70.5 |
| Month 6, n=46,43 | 73.9 | 67.4 |
Ocular Hyperaemia (excess of blood in the white of the eyes (sclera)) was graded by the investigator on a 4-point scale where 0=None/Trace, 1=Mild, 2=Moderate, and 3=Severe. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
| participants | TRAVATAN | LUMIGAN |
|---|---|---|
| Baseline, Grade 0 | 40 | 31 |
| Baseline, Grade 1 | 9 | 17 |
| Baseline, Grade 2 | 1 | 1 |
| -1 Grade Change from Baseline at Week 6 | 2 | 1 |
| 0 Grade Change from Baseline at Week 6 | 20 | 23 |
| +1 Grade Change from Baseline at Week 6 | 23 | 20 |
| +2 Grade Change from Baseline at Week 6 | 1 | 2 |
| -1 Grade Change from Baseline at Month 3 | 2 | 1 |
| 0 Grade Change from Baseline at Month 3 | 13 | 15 |
| +1 Grade Change from Baseline at Month 3 | 25 | 26 |
| +2 Grade Change from Baseline at Month 3 | 6 | 2 |
| -1 Grade Change from Baseline at Month 6 | 0 | 1 |
| 0 Grade Change from Baseline at Month 6 | 20 | 15 |
| +1 Grade Change from Baseline at Month 6 | 23 | 25 |
| +2 Grade Change from Baseline at Month 6 | 3 | 2 |
Corneal staining was assessed after ophthalmic dye was instilled in the eye. The upper eyelid was lifted slightly, and the eye was compared to grading panels. Corneal staining was graded on a scale from 0 (absent) to 5 (severe). One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
| participants | TRAVATAN | LUMIGAN |
|---|---|---|
| Baseline, Grade 0 | 41 | 39 |
| Baseline, Grade 1 | 8 | 9 |
| Baseline, Grade 2 | 1 | 1 |
| -1 Grade Change from Baseline at Month 3 | 7 | 4 |
| 0 Grade Change from Baseline at Month 3 | 33 | 33 |
| +1 Grade Change from Baseline at Month 3 | 6 | 7 |
| -1 Grade Change from Baseline at Month 6 | 4 | 7 |
| 0 Grade Change from Baseline at Month 6 | 28 | 25 |
| +1 Grade Change from Baseline at Month 6 | 13 | 10 |
| +2 Grade Change from Baseline at Month 6 | 1 | 1 |
Conjunctiva staining was assessed after ophthalmic dye was instilled in the eye. The upper eyelid was lifted slightly, and the eye was compared to grading panels. Conjunctiva staining was graded on a scale from 0 (absent) to 5 (severe). One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
| participants | TRAVATAN | LUMIGAN |
|---|---|---|
| Baseline, Grade 0 | 44 | 39 |
| Baseline, Grade 1 | 6 | 9 |
| Baseline, Grade 2 | 0 | 1 |
| Month 3, -1 Grade Change from Baseline | 6 | 6 |
| Month 3, 0 Grade Change from Baseline | 36 | 33 |
| Month 3, +1 Grade Change from Baseline | 3 | 5 |
| Month 3, +2 Grade Change from Baseline | 1 | 0 |
| Month 6, -1 Grade Change from Baseline | 4 | 7 |
| Month 6, 0 Grade Change from Baseline | 31 | 26 |
| Month 6, +1 Grade Change from Baseline | 11 | 9 |
| Month 6, +2 Grade Change from Baseline | 0 | 1 |
The OSDI questionnaire (used to measure vision-related function, ocular symptoms, visual function, and environmental factors that may affect vision) was answered by the subject. Each of the 12 items was scored on a 0-4 Likert scale, where 0 is "None of the time" and 4 is "All of the time." A resultant overall 0-100 score was calculated, with higher scores representing greater disability. A negative number change represents a perceived improvement in ocular health.
| units on a scale | TRAVATAN | LUMIGAN |
|---|---|---|
| Baseline (Day 0) | 14.6 ± 14.8 | 10.6 ± 10.5 |
| Change from Baseline at Month 3, n=44,43 | -0.3 ± 12.2 | 0.0 ± 10.4 |
| Change from Baseline at Month 6, n=44,42 | 0.4 ± 16.2 | 1.7 ± 14.3 |
TBUT (the time required for dry spots to appear on the corneal surface after blinking) was assessed by the investigator using slit lamp examination . A longer break up time is a sign of a more stable tear film. A positive number change from baseline indicates improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.
| seconds | TRAVATAN | LUMIGAN |
|---|---|---|
| Baseline (Day 0) | 10.7 ± 2.7 | 11.7 ± 3.2 |
| Change from Baseline at Month 3, n=46,44 | -1.6 ± 5.3 | -1.8 ± 4.0 |
| Change from Baseline at Month 6, n=46,43 | -2.2 ± 3.6 | -2.2 ± 5.1 |
Collected over Adverse events (AEs) were collected for the duration of the study (Sep 2012 - Jun 2014). This analysis population includes all subjects who received at least 1 dose of either study treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TRAVATAN | — | 0/51 (0%) | 0/51 (0%) |
| LUMIGAN | — | 1/49 (2%) | 0/49 (0%) |
| Event | TRAVATAN | LUMIGAN |
|---|---|---|
| ThromboendarterectomySurgical and medical procedures | 0/51 | 1/49 |
This analysis population includes all randomized subjects.
| Age, Customized(participants) | TRAVATAN | LUMIGAN | Total |
|---|---|---|---|
| Under 60 years | 25 | 26 | 51 |
| 60 or more years | 27 | 26 | 53 |
| Sex: Female, Male(Participants) | TRAVATAN | LUMIGAN | Total |
|---|---|---|---|
| Female | 35 | 16 | 51 |
| Male | 17 | 36 | 53 |
No study locations are listed for this record.
The record gives a start of Sep 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost